Loading...
Please wait, while we are loading the content...
Similar Documents
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
| Content Provider | Scilit |
|---|---|
| Author | Newberry, Kate J. Patel, Keyur Masarova, Lucia Luthra, Rajyalakshmi Manshouri, Taghi Jabbour, Elias Bose, Prithviraj Daver, Naval Cortes, Jorge Kantarjian, Hagop Verstovsek, Srdan |
| Copyright Year | 2017 |
| Description | Key Points Survival of patients with MF after ruxolitinib discontinuation is poor, with median survival of 14 months. Low platelets at the start or end of therapy or clonal evolution while on therapy are associated with an even worse prognosis. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580275/pdf |
| Ending Page | 1131 |
| Page Count | 7 |
| Starting Page | 1125 |
| DOI | 10.1182/blood-2017-05-783225 |
| Journal | Blood |
| Issue Number | 9 |
| Volume Number | 130 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2017-08-31 |
| Access Restriction | Open |
| Subject Keyword | Hematology Survival Myelofibrosis Clonal Evolution Poor Worse Prognosis Platelets Journal: Blood (Vol- 111, Issue- 9) |
| Content Type | Text |
| Resource Type | Article |